Genentech R&D Combining Diagnostics With Drugs Throughout The Portfolio
This article was originally published in The Pink Sheet Daily
Avastin is one example where the drug’s mechanism of action may be too broad to warrant a companion diagnostic, CEO Levinson says.
You may also be interested in...
The guidance “is intended to describe some statistically appropriate practices for reporting results from different studies evaluating diagnostic tests and identify some common inappropriate practices,” FDA states in the document.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.